Are we REALLY at a 'turning point in the fight against Alzheimer's'? 打開 new 麻薬s 停止（させる） cruel 病気's 拒絶する／低下する... but 専門家s 警告する 手足を不自由にする／（物事を）損なうing 味方する 影響s (and cost) may outweigh any 利益s

• e-mail

It has already been 先触れ（する）d as the 'turning point' in the １０年間s-long war against Alzheimer's.

But questions about whether donanemab ― and two 類似の 麻薬s ― are really the answer to 戦闘ing the 破滅的な 病気 remain unanswered.

目印 裁判，公判 findings published today 明らかにする／漏らすd that donanemab, given as a once-月毎の infusion, slowed the 拒絶する／低下する of Alzheimer's by up to 60 per cent.

患者s in the earliest 行う／開催する／段階s of the memory-robbing 病気 were spared from the 必然的な より悪くするing of their symptoms.

製薬の 会社／堅い Eli Lilly, which owns the 麻薬,?発表するd it had already sought regulatory 是認 in the US. It 推定する／予想するs to 適用する for the same green light in the UK within six months.

However, 主要な 専門家s have 警告するd Britain is not ready to dish out the 資源-集中的な 麻薬, or 競争相手s lecanemab and aducanumab.

Donanemab is given to Alzheimer's 患者s through an IV infusion once a month. The monoclonal antibody ― a man-made 見解／翻訳／版 of proteins produced by the 団体／死体 to fight-off harmful 実体s ― travels to the brain . Once inside the 組織／臓器, donanemab 貯蔵所d to 有毒な build-ups of amyloid plaque ― a hallmark 調印する of the memory-robbing 病気. This 誘発するs 免疫の 独房s, known as microglia, to （疑いを）晴らす them

研究員s today 明かすd that donanemab slowed cognitive 拒絶する／低下する in Alzheimer's by 35 per cent by 除去するing 有毒な plaques in the brain?

Others have 警告を与えるd they could be too expensive to 獲得する 是認, with price tags of around £16,000/year 存在 floated around the US, where the 初めの 麻薬s are already 利用できる.

Serious 関心s have also been raised about 味方する 影響s of the trio of 医薬s, which are designed to （疑いを）晴らす a 有毒な protein that builds up in the brain and is thought to be 責任がある memory loss.

専門家s also 示唆するd the 麻薬s' 影響s may not even be noticeable to 患者s or their families.

Donanemab, which has yet to be given a brand 指名する, was most 効果的な in under-75s in the earliest 行う／開催する／段階s of 病気.

研究員s 診察するd almost 1,800 people with 早期に-行う／開催する／段階 Alzheimer's. 患者s were either donanemab or a 模造の 麻薬 over 18 months.

関係者s at the earliest 行う／開催する／段階 of 病気 with 穏やかな cognitive impairment had the greatest 利益, with a 60 per cent slowing of 拒絶する／低下する compared to placebo.

の中で 患者s with 早期に Alzheimer's whose brain ざっと目を通すs showed low or medium levels of a protein called tau, the 麻薬 was 設立する to slow 臨床の 拒絶する／低下する by 35 per cent.

READ MORE:?Is this the 'beginning of the end' of Alzheimer’s 苦しむing? 打開 麻薬 signals '治療 時代' for memory-robbing 病気… but 専門家s 警告する the NHS is 'not ready' to dish it out

An 実験の Alzheimer's 麻薬 developed by Eli Lilly slows cognitive 拒絶する／低下する by more than a third, the company has said (在庫／株 image)

宣伝

When the results were 連合させるd for people who had different levels of this protein, there was a 22.3 per cent slowing in 病気 progression, によれば the findings published in the 定期刊行物 of the American 医療の 協会.

The same results, 広範囲にわたって 心配するd in the dementia field for months, were 同時に 現在のd at the Alzheimer's 協会 International 会議／協議会 in Amsterdam.?

Dr Richard Oakley, associate director of 研究 and 革新 at Alzheimer's Society, said: 'This is truly a turning point in the fight against Alzheimer's and science is 証明するing that it is possible to slow 負かす／撃墜する the 病気.

'治療s like donanemab are the first steps に向かって a 未来 where Alzheimer's 病気 could be considered a long-称する，呼ぶ／期間／用語 条件 と一緒に 糖尿病 or 喘息 - people may have to live with it, but they could have 治療s that 許す them to 効果的に manage their symptoms and continue to live 実行するd lives.'

The monoclonal antibody ― a man-made 見解／翻訳／版 of proteins produced by the 団体／死体 to fight-off harmful 実体s ― travels to the brain.

Once inside the 組織／臓器, donanemab 貯蔵所d to 有毒な build-ups of amyloid plaque ― a hallmark 調印する of the memory-robbing 病気. This 誘発するs 免疫の 独房s, known as microglia, to （疑いを）晴らす them.

However, like with any 医療の 治療, the 麻薬 is not 危険-解放する／自由な.

Serious 味方する 影響s such as brain swelling and bleeds were seen の中で some of the 患者s 同様に as three deaths linked to taking the 医薬.

'関心s remains over the 味方する 影響s of these 麻薬s - a 重要な 割合 of 患者s developed a form of brain oedema,' says?Dr Ivan Koychev, a 上級の 臨床の resear cher and 顧問 neuropsychiatrist at the University of Oxford.

Brain bleeds occurred in 314 患者s (36.8 per cent) in the donanemab group and 130 患者s (14.9 per cent) in the placebo group.

In the group that received donanemab, three 関係者s (0.4 per cent) died, which 研究員s said was linked to their 治療.

For comparison, there was one 治療-関係のある death (0.1 per cent) in the placebo group.

From 1906 when?臨床の psychiatrist ?Alois Alzheimer?first 報告（する）／憶測 ed a '厳しい 病気 of the cerebral cortex' to 暴露するing the mechanics of the 病気 in the 1980s-90s to today's '打開' 麻薬 lecanemab,? scientists have spent over a century trying to grapple with the 残虐な 病気 that 略奪するs people of their cognition and independence?

いっそう少なく than a year ago, another 麻薬, called lecanemab (pictured), was 設立する to 削除する cognitive 拒絶する／低下する の中で those with the memory-robbing 条件 by 27 per cen t

Dr Liz Coulthard, associate professor in dementia neurology at the University of Bristol, said 患者s will need to be aware of these '重要な 味方する 影響s' so they can choose whether to take the 麻薬s or not.

Professor Gill Livingston, an 専門家 in the psychiatry of older people at University College London, 公式文書，認めるd that the 医薬 carries '重要な 味方する 影響s' and there is 'still a lot of work to do to know wha t it means for most people with Alzheimer's'.

麻薬 製造者s are yet to 確認する the cost so it is 不明瞭な whether it will even reach 患者s in the UK, she 追加するd.

The 国家の 学校／設ける for Health and Care Excellence (NICE) considers the cost-有効性 of any new 認可するd 薬／医学, which is a 重要な factor in whether it is rolled out in Britain.

It looks at how 効果的な a 医薬 is, if any 競争相手 麻薬s work better and how much it costs in comparison to the next-best 治療.

Eli Lilly has not yet 確認するd donanemab's price, but 研究員s have 示唆するd it will cost $1,600 (£1,273) per dose or $20,000 (£15,909) 毎年.

Additionally, 専門家s have questioned the significance of the?donanemab results.

Dr Matthew Schrag, a neurologist at Vanderbilt University, told MailOnline that it is 'a bit of a しん気楼' to （人命などを）奪う，主張する that?donanemab slows the progression of Alzheimer's by a third.

He said: 'The 熟考する／考慮する 評価するd 患者s on the 統合するd Alzheimer’s 病気 率ing 規模, which 得点する／非難する／２０s 患者s on a 144 point 規模 (lower 得点する／非難する／２０s mean worse symptoms).?

'The difference between the 治療 and placebo groups was around 3 points, or 概略で a 2 per cent 絶対の difference.?

'This is the difference a 患者 or their family can 推定する／予想する to experience and it is a very small 影響?― small enough that most will not notice after 18 months of difficult and expensive 治療s.'

Dr Schrag 追加するd: 'We need to be 用心深い with this new group of 医薬s. I think it would be a mistake to 速く roll out these 治療 on a large 規模.

'These 麻薬s have serious 味方する 影響s, are difficult to 治める and I 恐れる they over-約束 結果s 関係のある to memory.?

'The fight for an 効果的な therapy is not over?― 患者s with Alzheimer’s need better 治療s than this.'?

Other roadblocks that could 妨げる donanemab becoming an Alzheimer's 治療 in the UK is the 複雑さs around 診断するing Alzheimer's 早期に and 治めるing the 麻薬.

Donanemab 作品 best when given to those at the earliest 行う／開催する／段階s of the 病気.

However, the NHS 公式文書，認めるs that it can take several 任命s and 実験（する）s over many moths before a doctor can 確認する whether someone has the memory-robbing 条件. Charities 警告する it can take longer than a year.

If donanemab is 認可するd, 患者s would then 要求する 付加 ざっと目を通すs, 含むing a PET ざっと目を通す to 手段 the 集中 of amyloid in the brain.?

患者s would also need to take cognitive 実験（する）s so medics could 監視する their mental abilities as they received 治療.

Then, once 治療 begins, 患者s would need to receive 月毎の infusions for up to 18 months, which is much more 資源-集中的な than taking 医薬 at home to manage the 条件?― the 現在の 治療 議定書.

Alzheimer's 苦しんでいる人s would also 要求する 正規の／正選手 ざっと目を通すs to 確実にする they were not experiencing 厳しい 味方する 影響s, such as brain bleeds.

専門家s have 以前 認める that the NHS is 'not ready' for the rollout of such 治療 and follow-up care.?

Dr?Coulthard said: 'The 資源 関わりあい／含蓄s of taking this sophisticated approach are enormous.?

'We need to transform our 接近 to brain ざっと目を通すs and infusion 控訴s and train a 技術d 全労働人口 to 配達する these 治療s.?

ワクチンs and antibodies, brain zapping helmets, oxygen therapy and 茎・取り除く 独房s are just some of the areas 専門家s are 調査するing in the 追跡（する） for a cure for Alzheimer's

'Alzheimer's is a ありふれた 条件, and we want people to be 適格の for 治療 on the basis of need, rather than 接近 存在 限られた／立憲的な to those who can afford 私的な care or live in 確かな areas of the country.'

Professor Paresh Malhotra, 長，率いる of neurology at 皇室の College London, said the NHS would need to 'adapt かなり' if?donanemab was 認可するd in the UK.

Other 専門家s question whether Alzheimer's 治療s should even be 取り組むing amyloid.?

The protein has long thought to be the 運動ing 軍隊 behind Alzheimer's.

However, a 2022 調査 by 最高の，を越す 研究 定期刊行物 Science 暴露するd 'shockingly 露骨な／あからさまの' tampering of results in a 重要な 2006 熟考する／考慮する 支持するing the amyloid hypothesis.?

And その後の 研究 has 示唆するd that the protein is only part of the story in 取り組むing Alzheimer's and cannot 申し込む／申し出 a cure.

Dr?John Sims, 上級の 医療の director at Eli Lilly today 確認するd that while donanemab doesn't cure Alzheimer's by 取り組むing amyloid, it can 供給する a 'very good 治療' and 延期する the progression of the 病気.

Around 850,000 Britons and 5.8million Americans have Alzheimer's 病気.?

The 病気 is the 主要な 原因（となる） of dementia, a 条件 where 苦しむs have an impaired?ability to remember, think, or make 決定／判定勝ち（する）s that 干渉するs with doing everyday activities.

Dementia 影響する／感情s 900,000 people in the UK and an 概算の 7million in the US.?

The 条件 is considered a 全世界の health 関心 as people live longer. It?puts an 増加するing 重荷（を負わせる） on health care systems 含むing in the UK.

扱う／治療するing and caring for 患者s with Alzheimer's 病気 and dementia is 概算の to cost Britain £25billion each year, によれば Alzheimer's 研究 UK, the 広大な 大多数 of that 存在 in social care spending.